Pharma’s Digital Directive: Not If, But How
Curing What Ails Alzheimer’s Drug Development
How Immuno-Oncology Is Turning Biomarker Development On Its Head
Orphans Should Live Alone
Immuno-Oncology Brings New Opportunities for Developers of Targeted Cytotoxics
The time is right to partner with immunotherapy firms, and for immunotherapy firms similarly to collaborate with those makers of targeted agents.
Immunotherapy: Big Pharmas Seductive Embrace
Launch or License: Taking Your First Drug To Europe